The delivery of therapeutic oligonucleotides remains a significant hurdle in the development of precision medicine. At CD BioGlyco, we specialize in overcoming these barriers through our advanced GalNAc-aptamer delivery service. This approach combines the high-affinity targeting of N-acetylgalactosamine (GalNAc) for the asialoglycoprotein receptor (ASGPR) with the structural versatility of aptamers. GalNAc is a well-established ligand for hepatocyte-specific uptake, while aptamers—single-stranded DNA or RNA sequences—act as "chemical antibodies" capable of binding specific molecular targets with high sensitivity. By conjugating GalNAc clusters to custom-engineered aptamers, we facilitate the precise delivery of therapeutic payloads directly to the liver, minimizing off-target effects and enhancing the therapeutic index of nucleic acid drugs.
1. Multivalent GalNAc Cluster Synthesis
CD BioGlyco utilizes proprietary synthetic pathways to create multivalent GalNAc clusters that exhibit significantly higher affinity for ASGPR compared to monovalent forms. This technology ensures robust internalization via receptor-mediated endocytosis.
2. Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
We employ an optimized SELEX process to identify aptamers with superior binding affinity and stability. This includes the integration of chemical modifications, such as 2'-fluoro or 2'-O-methyl substitutions, during the selection process to ensure the resulting GalNAc-aptamer conjugates are resistant to nuclease degradation in systemic circulation.
3. Precision Bioconjugation Chemistry
Our platform leverages site-specific conjugation techniques, including click chemistry and thiol-maleimide reactions, to link GalNAc ligands to aptamers. This ensures that the orientation of both the targeting ligand and the aptamer remains optimal for biological activity, preventing steric hindrance that could compromise delivery efficiency.
As a core component of our therapeutic nucleic acid development platform, CD BioGlyco provides a specialized therapeutic oligonucleotide delivery service focused on the development and validation of GalNAc-aptamer conjugates. Our services are designed to support researchers from the early discovery phase through to preclinical optimization.
We begin with a detailed review of your therapeutic goals and target gene specifications. Our experts assess the feasibility of the GalNAc-aptamer approach and recommend the most effective conjugation strategy based on the intended biological pathway.
Utilizing our SELEX platform, we identify or design aptamers with high specificity. We incorporate chemical modifications to enhance the half-life of the oligonucleotide, ensuring it survives the journey through the bloodstream to the liver.
Our chemists synthesize high-purity GalNAc clusters functionalized with appropriate reactive groups. These ligands are meticulously checked for structural integrity to guarantee maximum binding affinity for the hepatic ASGPR.
The GalNAc ligand and the aptamer are conjugated under mild, high-yield conditions. We maintain strict control over the stoichiometric ratio to ensure a homogeneous product that meets rigorous pharmaceutical standards.
We utilize high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to purify the conjugates and verify their molecular weight and purity. This ensures that every batch delivered is free from unreacted precursors or degraded fragments.
The final step involves testing the conjugate in cell-based models to confirm successful internalization and biological activity. We provide a comprehensive data report, including binding kinetics and intracellular localization studies.
DoI: 10.3390/biomedicines12010187
Journal: Biomedicines
IF: 3.9
Published: 2024
Results: This review focuses on aptamer-based smart targeting and stimuli-responsive drug-delivery systems for anticancer therapy. Aptamers, with high specificity and low immunogenicity, are conjugated with nanomaterials like gold, silica, and carbon, as well as organic materials such as liposomes, to enable precise drug delivery. Stimuli-responsive systems, triggered by internal (tumor microenvironment factors) or external (ultrasound, light, magnetic field) stimuli, achieve spatiotemporal controlled drug release. The integration of aptamers with stimuli-responsive strategies forms smart delivery systems, enhancing therapeutic efficacy while reducing side effects. The review also discusses future prospects, including optimized aptamer selection and theranostic applications, along with limitations like aptamer stability and mass production challenges that need to be addressed for clinical translation.
Fig.1 A variety of aptamer conjugates for targeted drug-delivery system. (Park, et al., 2024)
Hepatocellular Carcinoma (HCC) Research
GalNAc-aptamer conjugates allow for the specific delivery of tumor-suppressor nucleic acids or cytotoxic agents to cancerous hepatocytes, significantly reducing systemic toxicity.
Metabolic Disease Therapeutics
Our delivery service supports research into non-alcoholic steatohepatitis (NASH) and diabetes by enabling the targeted silencing of liver enzymes involved in lipid metabolism and glucose regulation.
Viral Infection Neutralization Research
For chronic infections like hepatitis B virus (HBV), GalNAc-aptamers deliver antiviral oligonucleotides directly to the site of replication, maximizing the local concentration of the drug.
Rare Genetic Liver Disorders
We assist in developing therapies for hereditary conditions such as transthyretin-mediated amyloidosis by delivering gene-editing or silencing tools specifically to the liver.
Enhanced Nuclease Resistance
CD BioGlyco incorporates advanced chemical modifications into every aptamer sequence, resulting in conjugates that are highly stable in human serum, thereby extending the window of therapeutic activity.
Optimized Binding Valency
Our ability to engineer multivalent GalNAc clusters allows for significantly increased binding avidity, which translates to faster internalization and higher intracellular concentrations of the therapeutic payload.
Low Immunogenic Profile
Unlike viral vectors or certain lipid-based delivery systems, our GalNAc-aptamer conjugates are designed to be minimally immunogenic, making them a safer choice for chronic administration.
Scalable Synthetic Process
We utilize robust chemical synthesis methods that are easily scalable, ensuring that your project transitions seamlessly from small-scale laboratory research to larger quantities required for extensive preclinical studies.
"The GalNAc-aptamer conjugates provided by CD BioGlyco were instrumental in our recent study on hepatic gene silencing. The specificity for hepatocytes was exceptional, and the technical support we received during the design phase was truly top-tier."
– D.S., Academic Institute of Hepatology
"They integrated seamlessly into our existing workflow, and the knockdown efficiency surpassed our previous delivery methods. A highly recommended partner for oligonucleotide research."
– B.W., Biotechnology Firm
"The team's expertise in carbohydrate chemistry and aptamer selection is evident. They helped us optimize a complex multivalent ligand that significantly improved our drug's bioavailability in liver models."
– D.F., Pharmaceutical R&D
CD BioGlyco is dedicated to advancing the field of therapeutic oligonucleotide delivery through innovation and scientific excellence. Our GalNAc-aptamer delivery service provides the precision and reliability necessary to move your liver-targeted therapies forward. Please feel free to contact us to help you design the optimal conjugate for your project.
Reference
